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c-Jun N-terminal kinase has a key role in Alzheimer
disease synaptic dysfunction in vivo
A Sclip1, A Tozzi2,3, A Abaza4, D Cardinetti1, I Colombo1, P Calabresi2,3, M Salmona1, E Welker4 and T Borsello*,1
Altered synaptic function is considered one of the first features of Alzheimer disease (AD). Currently, no treatment is available to
prevent the dysfunction of excitatory synapses in AD. Identification of the key modulators of synaptopathy is of particular
significance in the treatment of AD. We here characterized the pathways leading to synaptopathy in TgCRND8 mice and showed
that c-Jun N-terminal kinase (JNK) is activated at the spine prior to the onset of cognitive impairment. The specific inhibition of
JNK, with its specific inhibiting peptide D-JNKI1, prevented synaptic dysfunction in TgCRND8 mice. D-JNKI1 avoided both the
loss of postsynaptic proteins and glutamate receptors from the postsynaptic density and the reduction in size of excitatory
synapses, reverting their dysfunction. This set of data reveals that JNK is a key signaling pathway in AD synaptic injury and that
its specific inhibition offers an innovative therapeutic strategy to prevent spine degeneration in AD.
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Alzheimer disease (AD) is characterized by loss of memory
and cognition and ultimately by massive neuronal death.
Substantial synaptic dysfunction is detected in the early
stages of AD when the hippocampus-dependent memory
deficit becomes clinically detectable.1–3
Evidence demonstrates that soluble Ab oligomers inter-
fered with the function of the excitatory synapses4–7 and
induced removal of glutamate receptors from the postsynaptic
density (PSD), leading to synaptopathy.8–15 Both N-methyl
D-aspartate receptors (NMDAr)16–20 and amino-3-hydroxy-5-
methyl-4isoxazole receptors (AMPAr)21,22 are affected. The
reduction of glutamate receptors correlates with the drop in
the synaptic levels of PSD-95, a postsynaptic scaffold protein
regulating the recruitment and maintenance of both AMPAr
and NMDAr within the postsynaptic membrane.21,23 Func-
tionally, Ab oligomers affect long-term potentiation (LTP)24
and long-term depression (LTD)25 by modulating glutamate
receptor and trigger aberrant patterns of neural network
activity.26
Although it’s now clear that synaptic loss correlates with
AD cognitive impairments, the intracellular mechanisms
leading to synaptic dysfunction/dysmorphogenesis remain
largely unexplained. Understanding the pathological
mechanisms is thus necessary to develop therapeutic
approaches aimed at protecting against synaptopathy or at
restoring its effect.
Because synaptic injury precedes neuronal death and
surviving neurons possess a remarkable capacity for synaptic
repair and functional recovery, we focus our efforts on the
development of a strategy to protect synapses.
We here characterized the early events leading to
synaptopathy in the hippocampus of TgCNRD8 mice, which
manifested the first cognitive defects at 3 months of age.27
As JNK’s role in synaptopathy has not yet been explored, we
combined detailed biochemical studies on the PSD with
morphological analyses and electrophysiological recordings
to unveil the central role of JNK in the mechanisms leading to
synaptic dysfunction.
We showed that JNK controls the first signs of spine
alterations in the brain and that its inhibition protects against
degeneration of dendritic spines in vivo. Our study sets the
basis for a novel target in AD therapy with particular regard to
early synaptic dysfunction.
Results
Characterization of synaptopathy in TgCRND8 mice. To
characterize the synaptic dysfunction in TgCRND8 mice, we
isolated the postsynaptic elements using a well-established
biochemical approach.28 The triton insoluble fraction (TIF)
enriched in postsynaptic proteins was extracted from
hippocampi of TgCRND8 mice and age-matched wild-type
mice. To verify whether synaptic dysfunction occurred before
the onset of cognitive deficits in this mouse strain,27 samples
from 2-months-old mice were used. At this stage TgCRND8
mice already showed significantly reduced levels of GluN2A
(31%) and GluN2B (54%) subunits of NMDAr; GluA1 (46%)
and GluA2 (35%) subunits of AMPAr and a loss of
postsynaptic markers like PSD-95 (35%) and drebrin (60%)
(Student’s t-test, Po0.05) (Figures 1a–h).
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At 9 months of age, TgCRND8 presented a significant drop
of glutamate receptor subunits: GluN2A (74%), GluN2B (86%),
GluA1 (66%) andGluA2 (71%) (Figures 1i–m) (Student’s t-test,
Po0.05). Similarly PSD-95 (80%) and drebrin (84%) were
considerably reduced if compared with age-matched wild-type
mice (Figures 1n and o) (Student’s t-test, Po0.05).
We thus proved that synaptopathy started (2 months)
altering the biochemical composition of the PSD before the
manifestation of cognitive impairment (3 months) and the
severity of PSD changes increased with age in TgCRND8
mice.
The JNK signaling pathway in synaptopathy. We then
analyzed JNK activation at the postsynaptic level
in TgCRND8 mice at 2 months, just before the manifestation
of the cognitive impairment and at 9 months of age, when
mice were severely affected. The western blot analyses
demonstrated a significant activation of the JNK pathway in
the postsynaptic compartment, already at 2 months of age
and this correlated with the first biochemical changes in the
PSD region of dendritic spines. The activated form of JNK
was increased already in the pre-symptomatic stage (1.87-
fold, Figures 2a and b) (Student’s t-test, Po0.05), and was
further augmented in 9-months-old TgCRND8 mice (2.25-
fold; Figures 2c and d) (Student’s t-test, Po0.01) in
comparison with values obtained from age-matched, wild-
type mice. These results indicated that JNK is implicated in
the early phase of synaptic alterations, as its activation
coincides with the first biochemical changes at the synaptic
level and occurs before the manifestation of cognitive
deficits. Importantly, JNK activation persisted and increased
in time during synaptopathy progression in TgCRND8 mice.
Specific JNK inhibition prevents biochemical changes
of the PSD region. To clarify the role of JNK in synapto-
pathy, we chronically treated TgCRND8 mice to with the
specific JNK inhibitor peptide D-JNKI1 in order to prevent
JNK action. Vehicle-treated mice were used as controls.
Control peptides (TAT-empty and TAT-mutated peptides)
were already tested in the same model and resulted to have
any effect at the biochemical as well as at the electro-
physiological levels.29 The treatment was started at the 4th
month of age when the mice already showed cognitive
decline29 as well as biochemical changes in the postsynaptic
element (Figures 1a–h). Wild-type control mice were also
used for the treatment and received either the vehicle or
D-JNKI1. After 5 months of treatment, hippocampi from wild
type (wt) and TgCRND8 mice were dissected, processed for
PSD extraction and analyzed by western blot.
D-JNKI1-treated TgCRND8 mice showed a significant
increase in the levels of GluN2A, GluN2B, GluA1, GluA2,
PSD-95 and drebrin in comparison with the levels from
TgCRND8 mice treated with the vehicle (Figure 3a–h) (Two-
way ANOVA, interaction Po0.05, Bonferroni post-hoc test).
D-JNKI1 completely prevented alterations in the PSD
composition since protein levels were similar to age-matched
wt animals. D-JNKI1-treated wt mice did not present any
change in PSD proteins (Figure 3a). As expected, D-JNKI1
treatment abolished also caspase-3 cleavage in TgCRND8
mice (Figures 3i and j) (Two-way ANOVA, interaction Po0.05,
Bonferroni post-hoc test). D-JNKI1 chronic treatment com-
pletely blocks biochemical alterations of PSD of TgCRND8.
Specific JNK inhibition protects spines from dysmor-
phogenesis. To study structural alterations of excitatory
synapses we quantitatively analyzed the ultrastructure of
volumes of neutrophil sampled at the level of the stratum
radiatum of the hippocampus (Figure 4a) of three groups of
mice: TgCRND8 mice that had been treated with D-JNKI1 for
5 months (total volume analyzed: 608.82 mm3); age-matched
wt (926.43 mm3) and TgCRND8 (973.41 mm3) mice that had
been injected with the vehicle during the same period of time
(Figures 4b–e). We compared the PSD area of the excitatory
synapses on spines and found significant differences among
the three groups: in the vehicle-treated TgCRND8 mice PSD
area was significantly smaller than in the Wt mice (30%
reduction), whereas the D-JNKI1 treatment reversed this
difference of area to the wild-type mice (Figure 4d) (One-way
ANOVA, Po0.05, Bonferroni post-hoc test). The measure-
ments of the spine volume showed a similar sequence of
results (32% reduction) (Figures 4c and e) (One-way
ANOVA, Po0.05, Bonferroni post-hoc test). The EM-
observations show a similar trend as the biochemical data
and are in line with the hypothesis that D-JNKI1 treatment
reverse synaptic dysmorphogenesis in TgCRND8 mice.
Concerning spine loss, we found no differences in total
synaptic densities among the three groups of mice: Wt
mice (2.37±0.30 synapses per mm3); vehicle-treated
TgCRND8 mice (2.53±0.05); and the D-JNKI1-treated mice
(2.64±0.04) (data not shown).
JNK-specific inhibition arrests synaptic impairment in
TgCRND8 mice. We previously proved that a chronic
administration of D-JNKI1 rescued cognitive impairment
and deficits of long-term potentiation (LTP) of excitatory
postsynaptic response in the CA1 region of TgCRND8
mice.29 We here explored the effect of D-JNKI1 treatment
on long-term depression (LTD). LTD is an activity-dependent
physiological phenomenon occurring in the dentate gyrus
(DG) that also involves synaptic release of glutamate.
Previously, it was shown that LTD in the DG was increased
in models of AD.6 We therefore investigated the basis for the
functional recovery after D-JNKI1 treatment by measuring
LTD in hippocampal slices from TgCRND8 and Wt mice.
As shown in Figures 5a–c, a low-frequency stimulation (LFS)
protocol applied in slices from 9-months-old Tg mice
produced an abnormally enhanced LTD in the DG as
compared to LTD measured in slices from age-matched Wt
animals (reduction of population spike (PS) amplitude, Tg
48±3.9% versus Wt 19.3±5.9%; Two-way ANOVA,
Po0.001). TAT-control peptide did not have any effects on
LTD (data not shown) as already reported for previous
studies.29 In order to test whether the acute effect of D-JNKI1
in recovering spine function in Tg mice correlated with a
possible recovery to physiological levels of the altered DG
LTD, we performed field potential recordings in hippocampal
slices treated with D-JNKI1. LFS protocol applied in slices
from Tg mice incubated with D-JNKI1 (3 mM for 2 h) produced
LTD of synaptic transmission in the DG region that was
smaller in respect to LTD measured in non-treated slices
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Figure 1 Synaptopathy occurred in TgCRND8 mice, already at an early stage of AD pathology. (a–h) Western blot and relative quantification performed on the TIF fraction
of 2-months-old Wt and TgCRND8 mice. Tg mice showed a significant reduction in the PSD levels of GluN2A (31%) (b) and of GluN2B (54%) (c) subunits of NMDAr, as well as
reduction of GluA1 (46%) (d) and of GluA2 (35%) (e) subunits of AMPAr, of PSD-95 (35%) (f) and of drebrin (60%) (g) if compared with age-matched Wt mice (Student’s t-test,
*Po0.05, **Po0.01, ***Po0.001, n¼ 6). Tubulin levels were not affected (h) (Student’s t-test, P40.05, n¼ 6). (i–p) Western blot and relative quantification performed on
the TIF fraction of 9-months-old Wt and TgCRND8 mice. Tg mice showed a severe reduction in the PSD levels of GluN2A (74%) (j) and of GluN2B (86%) (k) subunits of
NMDAr, as well as reduction of GluA1 (66%) (l) and of GluA2 (71%) (m) subunits of AMPAr, of PSD-95 (80%) (n) and of drebrin (84%) (o) if compared with age-matched Wt
mice (Student’s t-test, *Po0.05, **Po0.01, ***Po0.001, n¼ 6). Tubulin levels were not affected (p) (Student’s t-test, P40.05, n¼ 6)
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from Tg mice (reduction of PS amplitude, D-JNKI1
32.1±3.7% versus non-treated slices from Tg mice,
Two-way ANOVA, Po0.001). Thus, JNK-specific inhibition
with D-JNKI1 significantly reversed the alteration of LTD
observed in transgenic mice.
Discussion
In this study, we unveil a key role of JNK in triggering the
intracellular cascade leading to synaptopathy in TgCRND8
mice. JNK activation correlates with the first biochemical PSD
changes observed in TgCRND8 mice at 2 months of age,
before the onset of cognitive symptoms. These results are in
line with our in vitro studies showing that JNK activation
anticipates PSD changes in neurons treated with soluble Ab
oligomers.30 Moreover, specific inhibition of JNK completely
prevents degeneration of the postsynaptic compartment of
excitatory synapses in an in vivo model of AD, even if the
treatment was commenced after the onset of AD symptoms.
This forms a proof that JNK has a pivotal role in synaptopathy
and that synaptic degeneration is reversible. Dysfunctional
spines have in fact a large plasticity window, as their changes
can be reverted also two months after the beginning of the
spine degenerative process. The temporal window for
pharmacological intervention can thus be extended to a
‘post-symptomatic’ phase.
Unfortunately, the limitation is that none of the AD animal
models available reproduce exactly the human AD pathol-
ogy, since they do not show neuronal death. However, they
are useful tools to study synaptic dysfunction. Among AD
animal models, TgCRND8 mice showed a more extensive
spectrum of synaptic alterations compared to other AD
mouse models, characterized by mutations only in the APP
gene (APP23 and Tg2576 mice). In fact, Tg2576 mice were
reported to have decreased levels of GluA1,31 while APP23
mice showed alterations in the trafficking of synaptic NMDAR
subunits GluN2A andGluN2B, in the absence of PSD-95 and
AMPAr deficits.32 Importantly, TgCRND8 mice develop
memory impairment at 3 months of age27 and then
convincing long-term potentiation (LTP) deficits,29 making
them a suitable model for pre-clinical pharmacological
studies.
To investigate the role of JNK in the induction of synapto-
pathy and the neuroprotective effect of its inhibition, we
administered D-JNKI1 to TgCRND8 mice.27,29 We used a
‘post-symptomatic’ treatment as it is clinically more relevant.
This treatment protocol was also supported by our results that
demonstrate that JNK activation started at 2 months and
persisted with a significant increase during AD progression.
D-JNKI1 treatment completely reverted spine alterations:
preventing biochemical alterations of the PSD, restoring the
levels of NMDAr and AMPAr as well as PSD-95 and drebrin
in vivo as it did in vitro.30 Moreover, D-JNKI1 abolished at the
postsynaptic compartment activation of caspase-3, a pathway
implicated in AD spine death.30,31
To correlate the biochemical changes of the PSD regions
with morphological alterations at synapses, we performed
ultrastructural analysis of dendritic spines in the stratum
radiatum of the hippocampus.30 We demonstrated that
D-JNKI1 promotes a structural rescue of excitatory synapses,
as the PSD area and the volume of dendritic spines in
D-JNKI1-treated TgCNRD8 mice were compared with Wt-
mice levels. The ultrastructural observations are in line with
the biochemical data. In fact, the biochemical analysis
revealed that D-JNKI1 completely rescued alterations of the
PSD composition. However, we notice an inconsistency
between the EM (30% reduction) and the biochemistry (70%
reduction) quantification of the PSD region. This quantitative
difference between biochemical and ultrastructural data sets
could be explained by the fact that ultrastructural 3D
reconstructions were performed in a restricted region of the
hippocampus whereas the biochemical studies on the PSD
region were conducted using the whole hippocampus.
Unfortunately, TgCNRD8 did not reveal spine loss in the
brain region at the age studied. These results are supported
by other studies that described the presence of alterations in
spine morphology in the absence of changes in spine
numbers in others AD mouse models.33,34 Even without
evident spine loss, TgCNRD8mice showed synaptic dysfunc-
tion at 9 months of age and presented cognitive deficits
assessed with both behavioral and electrophysiological
analysis.29 Although the protective effect of D-JNKI1 on the
density of spines and synapses could not be proven in this
model, we have already shown that D-JNKI1 prevented spine
loss as well as PSD biochemical alterations30 in an in vitro
model of synaptopathy triggered by Ab-soluble toxic
Figure 2 JNK and caspase-3 pathways were activated in the postsynaptic
compartment in TgCRND8 mice. (a and b) Western blot and relative quantification
showing P-JNK and JNK levels in the TIF fraction of 2-months-old Wt and
TgCRND8 mice. P-JNK/JNK ratio was increased by 1.87-fold in TgCRND8 mice if
compared with the age-matched Wt mice (Student’s t-test, *Po0.05, n¼ 6). (c and
d) Western blot and relative quantification showing P-JNK and JNK levels in the TIF
fraction of 9-months-old Wt and TgCRND8 mice. P-JNK/JNK ratio was increased by
2.25-fold in TgCRND8 mice if compared with the age-matched Wt mice (Student’s
t-test, **Po0.01, n¼ 6)
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oligomers. A longitudinal study on synaptic density changes in
the hippocampus of TgCNRD8 mice would be needed to
identify the onset of the loss of excitatory synapses in this
mouse model of AD.
LTD recordings were performed to correlate the biochem-
ical/morphological changes to the altered synaptic function-
ality in TgCNRD8 mice. LTD is thought to result mainly from a
decrease in the PSD size and composition and strongly
Figure 3 D-JNKI1 prevented Ab-oligomers-induced loss of postsynaptic proteins from the PSD in TgCRND8 mice. (a–h) Western blot and relative quantification of TIF
fraction obtained from hippocampus homogenate of 9-months-old Wt and TgCRND8 mice, chronically treated with vehicle (water) or D-JNKI1 (22 mg/kg for 5 months).
TgCRND8 mice treated with vehicle showed a strong loss of GluN2A (b) and GluN2B (c) subunits of NMDAr, GluA1 (d) and GluA2 (e) subunits of AMPAr, PSD-95 (f) and
drebrin (g) from the PSD. D-JNKI1 chronic treatment completely prevented these alterations in Tg mice, whereas it did not affect protein levels in Wt mice (two-way analysis of
variance (ANOVA), Bonferroni post-hoc test, *Po0.05, **Po0.01 Wt veh versus Tg veh; #Po0.05, ##Po0.01 Tg veh versus Tg D-JNKI1; yPo0.05 Wt D-JNKI1 versus Tg
D-JNKI1, n¼ 6). Tubulin levels (h) were not affected by the treatment or by mice genotype. (i and j) Western blot and relative quantification showing cleaved caspase-3 levels
in the TIF fraction of 9-months-old Wt and TgCRND8 mice treated with vehicle (water) or D-JNKI1 (22 mg/kg for 5 months). D-JNKI1 chronic treatment completely prevented
activation of caspase-3 in TgCRND8 mice (Two-way ANOVA, Bonferroni post-hoc test, **Po0.01 Wt veh versus Tg veh; ##Po0.01 Tg veh versus Tg D-JNKI1, n¼ 6)
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Figure 4 D-JNKI1 prevented morphological alterations in dendritic spines observed in TgCRND8 mice. Alteration in spine morphology was assessed by performing serial
sectioning electron microscope analysis. (a) Micrograph of a section through the hippocampus showing the position of the neutrophil sampled at the level of the stratum
radiatum of the hippocampus. The black box shows the position of the block whereas the asterisk represent the site of the analysis. (b) Electron micrographs showing
excitatory synapses on spines in TgCRND8 mice treated with vehicle (Tg veh) or with 22 mg/kg D-JNKI1 (Tg D-JNKI1). D-JNKI1 treatment induced an increase in the PSD (red
in figure) area and in the postsynaptic spine (green in figure) volume if compared with vehicle-treated TgCRND8 mice. (c) Three-dimensional EM reconstruction illustrating
dendritic segments from TgCRND8 mice treated with vehicle or D-JNKI1; note the appearance of large spines in the D-JNKI1-treated case. (d and e) Graphs showing the
effect of D-JNKI1 treatment on PSD area (d) and in spine volume (e) in TgCRND8 mice. TgCRND8 mice show a significant reduction in the PSD area (30%) (d) and spine
volume (32%) (e). D-JNKI1 treatment restores normal sizes of spines and PSD area (one-way ANOVA, Bonferroni post-hoc test, *Po0.05 Wt veh versus Tg veh; ###Po0.001
Tg veh versus Tg D-JNKI1, Wt veh n¼ 122 spines, Tg veh n¼ 168 spines; TgCRND8 D-JNKI1 n¼ 178 spines)
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correlates with synaptopathy.35,36 TgCRND8 mice presented
an increased LTD, which was reverted by D-JNKI1 treatment
in 9-months-old AD animals. Thus, JNK inhibition normalized
the altered hippocampal synaptic plasticity by restoring LTD
impairment as well.
All together, these data indicate that JNK activation triggers
and controls synaptopathy in TgCNRD8 transgene-depen-
dent phenotype mice. Moreover, JNK inhibition prevents
biochemical, morphological and functional alterations found in
TgCRND8 spines, even if the treatment is started after the
onset of AD pathology.
Until now, few studies addressed protection against
synaptopathy in vivo. Among them, there are controversial
data regarding the modulation of the g-secretase. The
selective blocker CHF5074 of this enzyme restored synaptic
plasticity in Tg2576mice,37 although it did not rescue synaptic
defects in a mouse model of familial Danish dementia.38
In addition, Chen et al.39 showed that an inhibitor of
calcineurin completely prevented Ab-induced LTP deficits in
wtmice. However, further comparison with our observations is
difficult as these studies did not report any data regarding
biochemical and morphological changes at synapses.
A recent report indicated that the pharmacological inhibition
of caspase-3 rescued synaptic failure and memory deficits
in Tg2576 mice.31 In this study, the authors proved that
inhibition of caspase-3 reduced GluA1 dephosphorylation and
removal from the PSD, and also reversed hippocampal
function deficits at the onset of AD.
D-JNKI1 neuroprotective effect succeeded in preventing
not only GluA1 loss at the PSD of glutamatergic synapses but
also GluA2 subunits of AMPAr, GluN2A and GluN2B subunits
of NMDAr, as well as two important postsynaptic proteins:
PSD-95 and drebrin. This probably suggests that JNK
controls the removal of both AMPAr and NMDAr by regulating
PSD-95 abundance at the PSD as suggested in another
model.40 PSD-95 and caspase-3 have been identified as JNK
targets.40,41 In fact, D-JNKI1 blocked both PSD-95 loss and
caspase-3 cleavage in the PSD region, preventing spine
degeneration.30 Inhibition of JNK is therefore the most
efficient neuroprotective strategy currently known against
synaptopathy.
D-JNKI1 treatment was conducted 1 month after the
onset of cognitive defects and PSD changes in TgCRND8
mice. The JNK inhibition completely prevented glutamatergic
synaptopathy, indicating a high potentiality of the
treatment within an interesting window of intervention. We
believe that the powerful effect obtained with D-JNKI1 is
linked to its outcome on maintenance of the postsynaptic
element structure and functionality, but it is also due
to its effect on APP phosphorylation and cleavage, which
contributes to Ab oligomers formation, LTP impairment29 and
Tau hyperphosphorylation.42 In fact, we had previously
proven that JNK is involved in APP phosphorylation at Thr-
668 and is consequently implicated in the production of
soluble Ab oligomers. Taken together these results suggest
that JNK is a key pathway in AD; in fact, JNK triggers spine
dysfunction but it also contributes to the progression of the
pathology regulating the production of the toxic soluble Ab
oligomers.
D-JNKI1 was designed to prevent c-Jun phosphorylation,43,44
which regulates a multitude of intracellular signaling related
to stress and cell death.45 This is another important effect
carried in TgCRND8 mice that explains its powerful neuro-
protective role in vivo.
In conclusion, all together these results set the basis for the
development of a JNK-based therapeutic strategy targeting
synapses for the treatment of AD.
Materials and Methods
Transgenic mice and pharmacological treatments. Experimental
procedures on animals were conducted in accordance with the European
Communities Council Directive (86/609/EEC) and were authorized by Italian legal
Figure 5 D-JNKI1 restored synaptic function in TgCRND8 mice. Electrophysiological analysis. (a) Example pairs of traces of field potentials showing population spikes
(PS) evoked before and after the induction of LTD by a LFS protocol in hippocampal slices cut from Wt (left) and TgCRND8 mice (center) and in hippocampal slices from Tg
mice incubated with D-JNKI1 (3 mM, 2 h) (right). (b) Time-course graph of population spike (PS) amplitudes showing LTD induced by LFS protocol in slices from Wt mice
(diamonds), Tg mice (open circles) and in slices from Tg mice incubated with D-JNKI1 (red-filled circles) (two-way ANOVA, ***Po0.001 Wt versus Tg, ###Po0.001 Tg versus
Tg D-JNKI1; Wt n¼ 11, Tg n¼ 8, Tg D-JNKI1 n¼ 4). (c) Histogram summarizing the reduction of the PS amplitude measured in control slices from Tg (white bar) compared
with Wt mice (black bar) (Student’s t-test, *Po0.05), and in slices from Tg mice incubated with D-JNKI1 (red bar) compared with the non-treated control slices from Tg mice
(Student’s t-test, #Po0.05)
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guidelines. All efforts were made to minimize the number of animals used and their
suffering. TgCRND8 mice27 were housed at 23 1C room temperature with food
and water ad libitum and a 12-h-light/dark cycle. TgCRND8 mice of either sex
were treated chronically with D-JNKI1 (IRCCS-Istituto di Ricerche Farmacologiche
‘Mario Negri’, Milan, Italy) diluted in water (22 mg/kg) or with water as vehicle
starting at 4–5 months of age. Mice received an intraperitoneal injection every 21
days for 5 months (six injections).
Subcellular fractionation (TIF). Subcellular fractionation was performed
as reported in the literature with minor modifications.28 Briefly, hippocampi were
dissected and homogenized in 0.32 M ice-cold sucrose buffer containing the
following (in mM): 1 HEPES, 1 MgCl2, 1 EDTA, 1 NaHCO3 and 0.1 PMSF, at pH
7.4, in the presence of a complete set of protease inhibitors (Complete; Roche
Diagnostics, Basel, Switzerland) and phosphatases inhibitors (Sigma, St. Louis,
MO, USA). Samples were centrifuged at 1000 g for 10 min. The resulting
supernatant (S1) was centrifuged at 13 000 g for 15 min to obtain a crude
membrane fraction (P2 fraction). The pellet was resuspended in 1 mM HEPES
plus protease and phosphatise inhibitor in a glass–glass potter and centrifuged at
100 000 g for 1 h. The pellet (P3) was resuspended in buffer containing 75 mM
KCl and 1% Triton X-100 and centrifuged at 100 000 g for 1 h. The final pellet
(P4) referred to as TIF was homogenized in a glass–glass potter in 20 mM HEPES
and stored at  80 1C until processing.
Western blot. Protein concentrations were quantified using the Bradford
Assay (Bio-Rad Protein Assay 500-0006, Munchen, Germany), and 10 mg of
whole-cell proteins or brain homogenates and 5 mg of TIF-extracted proteins were
separated by 10% SDS polyacrylamide gel electrophoresis. PVDF membranes
were blocked in Tris-buffered saline (5% no-fat milk powder, 0.1% Tween20) (1 h,
room temperature). Primary antibodies were diluted in the same buffer (incubation
overnight, 4 1C) using: anti GluN2A (1 : 2000, Gibco-Invitrogen, Paisley, Scotland,
UK), anti GluN2B (1 : 2000, Gibco-Invitrogen), anti GluA1 (1 : 1000, Millipore,
Billerica, MA, USA), anti GluA2 (1 : 1000, Millipore), anti PSD-95 (1 : 2000,
Cayman Chemical Company, Ann Arbor, MI, USA), anti drebrin (1 : 2000, Assay
Design, Ann Arbor, MI, USA), P-JNK (G-7) (1 : 1000, Cell Signaling Technology,
Danvers, MA, USA), JNK (1 : 1000, Cell Signaling Technology), Cleaved caspase-
3 (1 : 1000, Cell Signaling Technology). All blots were normalized to Tubulin
(1 : 5000, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and at least three
independent experiments were performed. Blots were developed using horse-
radish peroxidase-conjugated secondary antibodies and the ECL chemilumines-
cence system. Western blots were quantified by densitometry using Quantity One
software (Bio-Rad, Hercules, CA, USA).
Serial section electron microscopy. Vehicle- and D-JNKI1-treated
TgCRND8 mice and age-matched wild-type mice (age: 9 months; number of mice
used: total of eight; Wt veh n¼ 2, Tg veh n¼ 3 and Tg D-JNKI1 n¼ 3) were deeply
anesthetized with Nembutal (60 mg/kg, i.p.) and perfused through the heart with
300 ml of fixative (2.5% glutaraldehyde and 2% paraformaldehyde in cacodylate
buffer, 0.1 M (pH 7.4). One hour after perfusion, the brain was removed and
vibratome sections were cut at 60mm tangential to the dorsal surface of the brain.
Sections were washed in 0.1 M cacodylate buffer, stained with 1.5% potassium
ferrocyanide in osmium tetroxide (1% in 0.1 M cacodylate buffer, pH 7.4), and with
osmium tetroxide alone, then with uranyl acetate. Sections were dehydrated in
alcohol and in propylene oxide and embedded in Durcapan ACM resin (Fluka,
Neu-Ulm, Germany) between silicon-coated glass slides.
After the resin hardened, the stratum radiatum of CA1 region of the hippocampus
was identified and trapezoid blocks were prepared within this region. Series of
100–130 sections were cut at 50 nm (ultracut UCT microtome; Leica, Wetzlar,
Germany) and collected on Formvar support film on single-slot copper grids.
Sections were washed in bi-distilled water and contrasted with lead citrate.
Serial images of the stratum radiatum part of CA1 region were collected using
Morada CCD camera and iTEM software (Olympus, Munster, Germany) on a Philips
CM10 electron microscope (filament voltage 80 kV), aligned and analyzed using Fiji
software (http://fiji.sc/wiki/index.php/Fiji).
Morphometric analysis of spines and synapses. Morphometric
analysis on the densities of excitatory and inhibitory synapses on shaft and spines
was accomplished on volumes of neuropil from Wt veh (n¼ 2; total volume
analyzed: 609mm3), Tg veh (n¼ 3; total volume analyzed: 973mm3) and TgD-
JNKI1 (n¼ 3; total volume analyzed: 926mm3) mice.
The thickness of the sections in the stack was calculated by measuring the
diameter of longitudinally cut mitochondria and determining the number of sections
in which the mitochondria were found as previously described.46
Synapses were identified by vesicle number (n43), shape, clarity and
postsynaptic density (PSD) thickness across electron micrographs taken from
three consecutive sections. Spine volumes and PSD area were measured on
randomly selected asymmetric synapses (Wt veh, n¼ 122, Tg veh, n¼ 168; Tg
D-JNKI1, n¼ 179) within the analyzed volume of each mouse. For PSD-area
analysis, a line segment was drawn along the postsynaptic density (the electron
dense plaque on the postsynaptic membrane opposed to the presynaptic element)
in each section through a given synapse using polyline tool in Fiji software. For each
synapse, the sum of the length of the lines was multiplied by the section thickness
resulting in the PSD area. The analysis was made in double-blind, that is, without
knowing the identity of the animal under study.
Electrophysiology. Mice were decapitated and the brain was removed and
immersed for 2–3 min in ice-cold artificial CSF (ACSF) containing (in mM): 126
NaCl, 2.5 KCl, 1.2 MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 10 glucose and 25 NaHCO3,
continuously bubbled with 95% O2 and 5% CO2, pH 7.4. The hippocampus was
extracted and cut in ice-cold ACSF with a vibratome (Pelco 1000 plus; Redding,
CA, USA) into 400-mm-thick transverse slices, which were allowed to recover in
oxygenated ACSF at 30 1C for 30 min, and then at room temperature for another
1–2 h before experimental recordings. For D-JNKI1 treatment, slices were
incubated in oxygenated ACSF containing 3 mM D-JNKI1 for 2 h before the onset
of recording. A slice was transferred into the recording chamber and submerged in
ACSF at a constant rate of 2.5 ml/min at 30 1C. Recording electrodes were made
of borosilicate glass capillaries (GC150F-10; Harvard Apparatus, Holliston, MA,
USA) and filled with 2 M NaCl (resistance 10–15 MO). Under visual control, the
stimulating electrode was inserted into the Perforant pathway, and the recording
electrode into the granular layer of the dentate gyrus (DG). Testing stimuli at
0.1 Hz, 10ms duration and 20–30 V amplitude evoked field potential responses of
50–70% of maximal amplitude, that included population spikes (PS). Field
potentials were filtered at 3 KHz, digitized at 10 KHz and stored on a PC. An
Axoclamp 2B amplifier (Axon Instruments, Union City, CA, USA) was used for
extracellular recordings. After recording a stable baseline for 20 min, long-term
depression (LTD) was induced by a low-frequency stimulation (LFS) delivered for
15 min at 1 Hz at a stimulus used during baseline recording. After LFS onset, the
PS amplitude time-course was followed for at least 60 min.
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